Palmitoylethanolamide Reduces Proinflammatory Markers in Unvaccinated Adults Recently Diagnosed with COVID-19: A Randomized Controlled Trial

Overview

Journal J Nutr

Publisher Elsevier

Specialty Nutritional Sciences

Date 2022 Sep 9

PMID 36084236

Authors

Samantha N Fessler

Li Liu

Yung Chang

Theresa Yip

Carol S Johnston

Affiliations

Soon will be listed here.

Abstract

Background: Inflammation is at the core of many chronic conditions and exacerbates infectious conditions, including the severity of coronavirus disease 2019 (COVID-19) infections.

Objectives: This study aimed to examine the effects of a novel food supplement, palmitoylethanolamide (PEA), specifically Levagen+, as compared with a placebo on proinflammatory biomarkers in adults recently diagnosed with COVID-19 who were unvaccinated and nonhospitalized.

Methods: This study was a double-blind randomized placebo-controlled trial conducted October 2020-March 2021 (clinicaltrials.gov: NCT04912921). Participants aged 19-53 y were unvaccinated and recently infected with COVID-19 as indicated by a positive test result per RT-PCR or antigen test, and they reported to the test site following diagnosis as allowed by the CDC's return-to-work policy. Participants were stratified by age, sex, and BMI and randomly assigned by coin toss to receive 600 mg Levagen+ twice daily (LEV) or placebo tablets twice daily (CON) for 4 wk. At baseline and week 4, participants completed health histories, 24-h dietary recalls, anthropometrics, and nonfasting blood sampling. The primary outcomes were the 4-wk change between groups for IL-6, C-reactive protein, ferritin, intercellular adhesion molecule 1, soluble P-selectin (sP-selectin), and neutrophil/lymphocyte ratio. Multiple linear regression models were utilized to assess treatment effects on outcomes, adjusting for covariates.

Results: A total of 60 participants completed the study (LEV: n = 30; CON: n = 30). After 4 wk of supplementation, sP-selectin (β = -11.5; 95% CI: -19.8, -3.15; P = 0.0078), IL-1β (β = -22.9; 95% CI: -42.4, -3.40; P = 0.0222), and IL-2 (β = -1.73; 95% CI: -3.45, -0.065; P = 0.0492) concentrations were significantly reduced in the LEV group compared with the CON group.

Conclusions: Inflammatory mechanisms are crucial to optimal resolution of infectious conditions, yet unchecked secretion of inflammatory mediators can promote the dysregulated immune response implicated in COVID-19 complications. Overall, PEA supplementation produced anti-inflammatory effects in individuals recently diagnosed with COVID-19 who were nonhospitalized.

Citing Articles

Efficacy and Safety of the Combination of Palmitoylethanolamide, Superoxide Dismutase, Alpha Lipoic Acid, Vitamins B12, B1, B6, E, Mg, Zn and Nicotinamide for 6 Months in People with Diabetic Neuropathy.

Didangelos T, Karlafti E, Kotzakioulafi E, Giannoulaki P, Kontoninas Z, Kontana A Nutrients. 2024; 16(18).

PMID: 39339645 PMC: 11434759. DOI: 10.3390/nu16183045.

Body Mass Index Is Associated with Post-Acute Elevations in Biomarkers of Platelet Activation and Inflammation in Unvaccinated Adults Diagnosed with COVID-19 in the Previous 8 Weeks.

Fessler S, Liu L, Chang Y, Johnston C Obes Facts. 2024; 17(6):652-657.

PMID: 39116840 PMC: 11709689. DOI: 10.1159/000540343.

Effect of Palmitoylethanolamide Compared to a Placebo on the Gut Microbiome and Biochemistry in an Overweight Adult Population: A Randomised, Placebo Controlled, Double-Blind Study.

Batacan Jr R, Briskey D, Bajagai Y, Smith C, Stanley D, Rao A Biomedicines. 2024; 12(7).

PMID: 39062193 PMC: 11274356. DOI: 10.3390/biomedicines12071620.

Ultramicronized Palmitoylethanolamide and Luteolin: Drug Candidates in Post-COVID-19 Critical Illness Neuropathy and Positioning-Related Peripheral Nerve Injury of the Upper Extremity.

Roncati L, Marra C, Gravina D, Di Massa G, Della Rosa N, Adani R J Hand Microsurg. 2024; 16(2):100028.

PMID: 38855524 PMC: 11144630. DOI: 10.1055/s-0043-1764161.

Effect of anti-inflammatory drugs on the storm of inflammatory factors in respiratory tract infection caused by SARS-CoV-2: an updated meta-analysis.

Qin Z, Li Y, Sun W, Lu Y, Zhang N, Yang R Front Public Health. 2023; 11:1198987.

PMID: 37920591 PMC: 10619852. DOI: 10.3389/fpubh.2023.1198987.

References

Farsi F, Heshmati J, Keshtkar A, Irandoost P, Mesri Alamdari N, Akbari A . Can coenzyme Q10 supplementation effectively reduce human tumor necrosis factor-α and interleukin-6 levels in chronic inflammatory diseases? A systematic review and meta-analysis of randomized controlled trials. Pharmacol Res. 2019; 148:104290. DOI: 10.1016/j.phrs.2019.104290. View

Karsli E, Sabirli R, Altintas E, Canacik O, Tukenmez Sabirli G, Kaymaz B . Soluble P-selectin as a potential diagnostic and prognostic biomarker for COVID-19 disease: A case-control study. Life Sci. 2021; 277:119634. PMC: 8130002. DOI: 10.1016/j.lfs.2021.119634. View

Carvalho T, Krammer F, Iwasaki A . The first 12 months of COVID-19: a timeline of immunological insights. Nat Rev Immunol. 2021; 21(4):245-256. PMC: 7958099. DOI: 10.1038/s41577-021-00522-1. View

Furie B, Furie B . Role of platelet P-selectin and microparticle PSGL-1 in thrombus formation. Trends Mol Med. 2004; 10(4):171-8. DOI: 10.1016/j.molmed.2004.02.008. View

Riondino S, Pignatelli P, Pulcinelli F, Lenti L, Di Veroli C, Marigliano V . Platelet hyperactivity in hypertensive older patients is controlled by lowering blood pressure. J Am Geriatr Soc. 1999; 47(8):943-7. DOI: 10.1111/j.1532-5415.1999.tb01288.x. View

Liu Y, Yang Y, Zhang C, Huang F, Wang F, Yuan J . Clinical and biochemical indexes from 2019-nCoV infected patients linked to viral loads and lung injury. Sci China Life Sci. 2020; 63(3):364-374. PMC: 7088566. DOI: 10.1007/s11427-020-1643-8. View

Banu N, Panikar S, Leal L, Riera Leal A . Protective role of ACE2 and its downregulation in SARS-CoV-2 infection leading to Macrophage Activation Syndrome: Therapeutic implications. Life Sci. 2020; 256:117905. PMC: 7832382. DOI: 10.1016/j.lfs.2020.117905. View

Remy M, Alfter M, Chiem M, Barbani M, Engler O, Suter-Riniker F . Effective chemical virus inactivation of patient serum compatible with accurate serodiagnosis of infections. Clin Microbiol Infect. 2018; 25(7):907.e7-907.e12. PMC: 7128130. DOI: 10.1016/j.cmi.2018.10.016. View

Petito E, Falcinelli E, Paliani U, Cesari E, Vaudo G, Sebastiano M . Association of Neutrophil Activation, More Than Platelet Activation, With Thrombotic Complications in Coronavirus Disease 2019. J Infect Dis. 2020; 223(6):933-944. PMC: 7798977. DOI: 10.1093/infdis/jiaa756. View

10.

Mayadas T, Johnson R, Rayburn H, Hynes R, Wagner D . Leukocyte rolling and extravasation are severely compromised in P selectin-deficient mice. Cell. 1993; 74(3):541-54. DOI: 10.1016/0092-8674(93)80055-j. View

11.

Rockwell C, Snider N, Thompson J, Vanden Heuvel J, Kaminski N . Interleukin-2 suppression by 2-arachidonyl glycerol is mediated through peroxisome proliferator-activated receptor gamma independently of cannabinoid receptors 1 and 2. Mol Pharmacol. 2006; 70(1):101-11. DOI: 10.1124/mol.105.019117. View

12.

Man Y, Goreke U, Kucukal E, Hill A, An R, Liu S . Leukocyte adhesion to P-selectin and the inhibitory role of Crizanlizumab in sickle cell disease: A standardized microfluidic assessment. Blood Cells Mol Dis. 2020; 83:102424. PMC: 7246173. DOI: 10.1016/j.bcmd.2020.102424. View

13.

Lee C, Choi W . Overview of COVID-19 inflammatory pathogenesis from the therapeutic perspective. Arch Pharm Res. 2021; 44(1):99-116. PMC: 7781412. DOI: 10.1007/s12272-020-01301-7. View

14.

Gigante A, Aquili A, Farinelli L, Caraffa A, Ronconi G, Gallenga C . Sodium chromo-glycate and palmitoylethanolamide: A possible strategy to treat mast cell-induced lung inflammation in COVID-19. Med Hypotheses. 2020; 143:109856. PMC: 7236677. DOI: 10.1016/j.mehy.2020.109856. View

15.

Ivanov I, Apta B, Bonna A, Harper M . Platelet P-selectin triggers rapid surface exposure of tissue factor in monocytes. Sci Rep. 2019; 9(1):13397. PMC: 6746844. DOI: 10.1038/s41598-019-49635-7. View

16.

Levy J, Iba T, Gardiner E . Endothelial Injury in COVID-19 and Acute Infections: Putting the Pieces of the Puzzle Together. Arterioscler Thromb Vasc Biol. 2021; 41(5):1774-1776. DOI: 10.1161/ATVBAHA.121.316101. View

17.

Nomura S, Kanazawa S, Fukuhara S . Effects of efonidipine on platelet and monocyte activation markers in hypertensive patients with and without type 2 diabetes mellitus. J Hum Hypertens. 2002; 16(8):539-47. DOI: 10.1038/sj.jhh.1001447. View

18.

Pretorius E, Vlok M, Venter C, Bezuidenhout J, Laubscher G, Steenkamp J . Persistent clotting protein pathology in Long COVID/Post-Acute Sequelae of COVID-19 (PASC) is accompanied by increased levels of antiplasmin. Cardiovasc Diabetol. 2021; 20(1):172. PMC: 8381139. DOI: 10.1186/s12933-021-01359-7. View

19.

Zhao Y, Forst C, Sayegh C, Wang I, Yang X, Zhang B . Molecular and genetic inflammation networks in major human diseases. Mol Biosyst. 2016; 12(8):2318-41. PMC: 4955784. DOI: 10.1039/c6mb00240d. View

20.

Petrosino S, Di Marzo V . The pharmacology of palmitoylethanolamide and first data on the therapeutic efficacy of some of its new formulations. Br J Pharmacol. 2016; 174(11):1349-1365. PMC: 5429331. DOI: 10.1111/bph.13580. View